Published in Mol Cell Pharmacol on January 01, 2009
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS Biomater Sci Eng (2015) 0.95
Deacetylation by SIRT1 Reprograms Inflammation and Cancer. Genes Cancer (2013) 0.92
5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties. Bioorg Med Chem Lett (2012) 0.86
Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy. J Ovarian Res (2015) 0.83
Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents. Evid Based Complement Alternat Med (2014) 0.79
The effects of extracellular matrix proteins on neutrophil-endothelial interaction--a roadway to multiple therapeutic opportunities. Yale J Biol Med (2012) 0.79
Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila) (2016) 0.78
Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. Int J Nanomedicine (2016) 0.78
Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells. Int J Cancer (2015) 0.77
Microbial pigments as natural color sources: current trends and future perspectives. J Food Sci Technol (2014) 0.77
Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27. J Vet Med Sci (2016) 0.77
Withaferin A inhibits the proliferation of gastric cancer cells by inducing G2/M cell cycle arrest and apoptosis. Oncol Lett (2017) 0.76
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget (2016) 0.76
Synthetic high-density lipoprotein-like nanoparticles for cancer therapy. Expert Rev Anticancer Ther (2014) 0.76
NSAIDs and Cell Proliferation in Colorectal Cancer. Pharmaceuticals (Basel) (2010) 0.75
Glutathione S-transferase pi (GST-pi) inhibition and anti-inflammation activity of the ethyl acetate extract of Streptomyces sp. strain MJM 8637. Saudi J Biol Sci (2015) 0.75
A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity. Front Pharmacol (2016) 0.75
8-hydrocalamenene, derived from Reynoutria elliptica, suppresses constitutive STAT3 activation, inhibiting proliferation and enhancing chemosensitization of human multiple myeloma cells. J Med Food (2014) 0.75
Men's health supplement use and outcomes in men receiving definitive intensity-modulated radiation therapy for localized prostate cancer. Am J Clin Nutr (2016) 0.75
Inflammation and cancer. Nature (2002) 53.78
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11
High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer (2004) 5.99
Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 4.69
Prostaglandins and cancer. Gut (2005) 3.44
Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett (2008) 3.14
Course and outcome of chronic pancreatitis. Longitudinal study of a mixed medical-surgical series of 245 patients. Gastroenterology (1984) 2.60
Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res (2007) 2.52
Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res (2003) 2.49
Sulindac for polyposis of the colon. J Surg Oncol (1983) 2.34
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res (1988) 2.28
Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev (2004) 2.22
The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 2.17
Granulomatous inflammation--a review. J Clin Pathol (1983) 2.15
The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol (2004) 2.04
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol (2006) 1.99
Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal (2008) 1.99
Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res (2007) 1.95
Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate (2006) 1.90
Molecular mechanisms of aging-associated inflammation. Cancer Lett (2005) 1.80
Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets (2007) 1.63
Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol (1997) 1.63
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Use of dexamethasone in the treatment of cerebral edema resulting from brain tumors and brain surgery. Am Pract Dig Treat (1961) 1.59
Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res (2005) 1.49
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest (1999) 1.45
Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology (2002) 1.45
The growth-inhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro. Cancer Invest (2008) 1.44
Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol (2008) 1.42
Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. J Pharmacol Exp Ther (2002) 1.41
Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg (2004) 1.40
Inflammation, cancer, and targets of ginseng. J Nutr (2007) 1.39
Sexual factors and the risk of prostate cancer. Am J Epidemiol (2001) 1.38
Statins in tumor suppression. Cancer Lett (2008) 1.34
Involvement of chemokine receptors in organ-specific metastasis. Contrib Microbiol (2006) 1.32
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res (2008) 1.29
Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol (2005) 1.27
Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res (2004) 1.26
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res (2004) 1.25
Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol (2003) 1.24
The inhibition of croton oil-promoted mouse skin tumorigenesis by steroid hormones. Cancer Res (1972) 1.23
Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother (2008) 1.23
Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res (2008) 1.18
Advances in anti-emetic therapy. Cancer Treat Rev (1984) 1.18
Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J (2001) 1.17
Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst (2007) 1.17
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide (2008) 1.16
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol (2006) 1.16
Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs (2008) 1.15
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer (2008) 1.14
Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem (2006) 1.14
Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochim Biophys Acta (2005) 1.12
Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys (2007) 1.12
Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res (1993) 1.12
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer (2005) 1.12
Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol (2008) 1.11
Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer (2007) 1.11
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer (2008) 1.09
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer (2008) 1.07
Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol (2008) 1.06
Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am (2006) 1.05
Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther (2007) 1.05
Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J Med Chem (2000) 1.05
Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res (2006) 1.04
NSAIDs and apoptosis. Cell Mol Life Sci (2008) 1.04
Activation of the caspase-8/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis (2004) 1.04
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? Semin Oncol (2005) 1.04
Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun (2008) 1.03
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res (2007) 1.02
Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr Pharm Des (2007) 1.01
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys (2006) 0.98
Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs (2008) 0.98
The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene (2007) 0.98
Role of curcumin in health and disease. Arch Physiol Biochem (2008) 0.98
Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys (2004) 0.97
The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol (2008) 0.97
Antiproliferative effects of S-allylmercaptocysteine on colon cancer cells when tested alone or in combination with sulindac sulfide. Cancer Res (2001) 0.96
Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents. Anticancer Res (1987) 0.95
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol (2007) 0.93
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol (2004) 0.93
The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol (2007) 0.92
Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal (2008) 0.92
Self-report of prostatitis and its risk factors in a random sample of middle-aged men. Urology (2004) 0.91
Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy (2005) 0.90
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion (2007) 0.90
Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer (2006) 0.90
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother Pharmacol (2006) 0.90
Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Rev Anticancer Ther (2008) 0.90
Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol (2007) 0.90
Cancer cell: using inflammation to invade the host. Mol Cancer (2007) 0.89
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. Int J Cancer (2006) 0.88
High dose misonidazole with dexamethasone rescue: a possible approach to circumvent neurotoxicity. Int J Radiat Oncol Biol Phys (1982) 0.88
Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets (2008) 0.88
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol (2008) 0.87
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol (2008) 0.87
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev (2007) 0.86
Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. Int J Cancer (2008) 0.85
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol (2006) 2.33
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A (2003) 1.87
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83
Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets (2004) 1.72
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J (2008) 1.65
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res (2007) 1.60
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 1.51
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res (2008) 1.47
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today (2008) 1.37
Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front Pharmacol (2012) 1.35
RYBP stabilizes p53 by modulating MDM2. EMBO Rep (2008) 1.33
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med (2008) 1.32
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate (2008) 1.31
p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets (2005) 1.30
Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res (2005) 1.30
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res (2004) 1.25
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate (2003) 1.22
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res (2006) 1.22
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res (2009) 1.13
Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia. Int Immunopharmacol (2006) 1.13
Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2. PLoS One (2012) 1.09
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett (2009) 1.07
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther (2006) 1.05
Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer (2009) 1.00
Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish. Int J Biochem Cell Biol (2011) 1.00
Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. Med Res Rev (2014) 0.98
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res (2003) 0.98
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PLoS One (2011) 0.96
miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets (2013) 0.96
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res Treat (2009) 0.95
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res (2004) 0.94
Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm (2011) 0.94
Recent advances in validating MDM2 as a cancer target. Anticancer Agents Med Chem (2009) 0.94
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs (2009) 0.93
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol (2004) 0.93
Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs. Med Chem (2009) 0.93
Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Mar Drugs (2012) 0.91
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Mol Cancer Ther (2006) 0.91
Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther (2013) 0.91
MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J Biol Chem (2010) 0.90
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics. Curr Pharm Des (2005) 0.90
Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol (2007) 0.90
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med (2002) 0.90
Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun (2002) 0.90
Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One (2008) 0.90
Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J Biol Chem (2012) 0.88
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemother Pharmacol (2008) 0.87
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability. J Cell Physiol (2006) 0.87
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Cancer Epidemiol Biomarkers Prev (2007) 0.86
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One (2012) 0.86
Mode conversion based on forward stimulated Brillouin scattering in a hybrid phononic-photonic waveguide. Opt Express (2014) 0.85
JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One (2012) 0.85
Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets (2013) 0.85
CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun (2003) 0.85
Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol (2002) 0.85
Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB. Clin Cancer Res (2013) 0.84
Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs (2006) 0.84
Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells. Mol Cancer Ther (2013) 0.84
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res (2013) 0.84
T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate (2008) 0.84
Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis (2013) 0.83
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci (2003) 0.83
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent. Mar Drugs (2010) 0.83
Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol (2007) 0.83
Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. Eur J Drug Metab Pharmacokinet (2010) 0.83
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate (2006) 0.82
Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res (2002) 0.81
Oncogenes as novel targets for cancer therapy (part III): transcription factors. Am J Pharmacogenomics (2005) 0.81
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer (2002) 0.81
Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents. Curr Cancer Drug Targets (2013) 0.80
Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci (2005) 0.80
Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis. Am J Pharmacogenomics (2005) 0.80
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ. Curr Cancer Drug Targets (2013) 0.79
Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol (2005) 0.79
Recent advances in experimental molecular therapeutics for malignant gliomas. Curr Med Chem Anticancer Agents (2004) 0.79
Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer. J Cell Mol Med (2011) 0.79
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent. Cancer Chemother Pharmacol (2012) 0.78
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int J Oncol (2002) 0.78
Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer. Proteomics (2007) 0.78
Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharmacol (2005) 0.77
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol (2005) 0.77
Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr (2014) 0.77
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules. Am J Pharmacogenomics (2005) 0.77
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol (2007) 0.76
Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am J Pharmacogenomics (2005) 0.76
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharmacol (2005) 0.75
Analysis of threshold current of uniaxially tensile stressed bulk Ge and Ge/SiGe quantum well lasers. Opt Express (2017) 0.75
Analysis of acousto-optic interaction based on forward stimulated Brillouin scattering in hybrid phononic-photonic waveguides. Opt Express (2016) 0.75
Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal (2006) 0.75
Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. Methods Mol Biol (2015) 0.75
Antisense approaches in drug discovery and development. Prog Drug Res (2005) 0.75
Design and analysis of a CMOS-compatible distributed Bragg reflector laser based on highly uniaxial tensile stressed germanium. Opt Express (2017) 0.75